United Kingdom· GB-APID-42479511000001104
Litfulo 50mg capsules
A ritlecitinib product containing ritlecitinib, registered in United Kingdom by Pfizer Ltd. The same ATC class is registered in 16 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Ritlecitinib is registered in 16 of 19 countries.
Countries holding a registration under ATC L04AF08 (ritlecitinib), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 10 of them publish a price we can compare per daily dose
Ritlecitinib · ATC L04AF08
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Ritlecitinib
- Manufacturer
- Pfizer Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AF08
- ATC class
- Ritlecitinib
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5415062105474
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ritlecitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLitfuloU.S. Pharmaceuticals
- CzechiaLITFULOPfizer Europe MA EEIG, Bruxelles
- SwitzerlandLitfulo 50 mg, HartkapselnPfizer AG
- SpainLITFULO 50 MG CAPSULAS DURASPfizer Europe Ma Eeig
- FinlandLitfuloPfizer Europe MA EEIG
- FranceLITFULO 50 mg, gélulePFIZER EUROPE MA EEIG (BELGIQUE)
- BelgiumLitfulo 50 mgPfizer Europe MA
- IcelandLitfuloPfizer Europe MA EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Litfulo
- Liechtenstein · Litfulo
- Norway · Litfulo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f4c4ab01-34db-4d70-844b-691802198e57 GET /v1/drugs/f4c4ab01-34db-4d70-844b-691802198e57?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42479511000001104",
"desc": "Litfulo 50mg capsules (Pfizer Ltd)",
"form": "Oral capsule",
"vpid": "42545311000001100",
"source": "dmd",
"vtm_id": "42543211000001109",
"strength": "50 mg",
"substance": "Ritlecitinib",
"ingredient": "Ritlecitinib tosylate",
"supplier_code": "2082201000001106"
}See everything about ritlecitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.